B
BML
vs
W
WIG20
Over the past 12 months, BML has underperformed WIG20, delivering a return of 0% compared to the WIG20's +36% growth.
Stocks Performance
BML vs WIG20
Performance Gap
BML vs WIG20
Performance By Year
BML vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Glance View
Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 223 full-time employees. The company went IPO on 2011-07-29.